A Lyme disease vaccine produced by Pfizer and Valneva was deemed 70 percent effective by the companies after they reviewed the results from a phase 3 trial. If approved by regulators, it would be the first vaccine for humans against Lyme disease. “Lyme disease can cause potentially serious consequences – where individuals and families face…
